▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4141 by analyst upside · 2026-09-28
ADPT
Adaptive Biotechnologies Corporation
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
-10.4%
implied upside to consensus target
Current Price $29.43
Consensus Target $26.36
Bull Target $34.0
Bear Target $21.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
0
52-Week Low $12.0
52-Week High $29.96
YTD Return +85.0%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $308M
Profit Margin -20.7%
52-WEEK RANGE
52-Week Low $12.0
52-Week High $29.96
Current Price $29.43
Bear Target $21.0
Bull Target $34.0
● Now $29.43 ● Target $26.36
TRADING DATA
Avg Volume 2.4M
YTD Return +85.0%
Analyst Count 7
Consensus Buy
Upside to Target -10.4%
Last Updated 2026-09-28

ANALYST SUMMARY

Adaptive Biotechnologies Corporation (ADPT) is currently trading at $29.43 with a Wall Street consensus price target of $26.36, which is 10.4% below the current price over the next 12 months. 7 analysts currently cover ADPT, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $34.0, while the most cautious has a target of $21.0.

ADPT operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 85.0% year-to-date and is currently trading near the upper end of its 52-week range of $12.0 – $29.96.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ADPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG - Reiterated
Buy → Buy 2026-09-22 38% win rate (8 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-04 14% win rate (7 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-07-30 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-07-30 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-07-30 62% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-07-30 38% win rate (8 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-07-09 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-06-29 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
16/30
Consensus clarity
21/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →